• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[具有磷脂结构的血小板活化因子拮抗剂。4. 带有杂芳烃和杂环酶头部基团的烷基氨基甲酰磷脂以及P-N距离的变化;合成、表征及构效关系]

[PAF-antagonists with phospholipid structure. 4. Alkylcarbamoylphospholipids with heteroarene and heterocyclase head groups and variation of the P-N-distance; synthesis, characterization and structure-activity relationship].

作者信息

Kertscher H P, Schmidt B, Ostermann G

机构信息

Sektion Biowissenschaften, Universität Leipzig.

出版信息

Pharmazie. 1992 Mar;47(3):172-4.

PMID:1615020
Abstract

A series of 11 PAF-analogues, structurally modified in position 1 (alkylcarbamoyloxy), position 2 (n-propyl), and position 3 (polar head group) were synthesized, and the inhibitory potencies on human blood platelets in vitro was evaluated. Investigations of structure-activity relationships revealed, that the PAF antagonist activity is strongly influenced by the chain length of the alkylcarbamoyl residue and the structure of the polar head group. Derivatives with pentadecyl and octadecylcarbamoyl structure emerged effective inhibitors. The best activity was observed by dimethylaminopyridinium, analogues with a P-N distance of 3 or 4 methylene groups and pentadecyl or octadecylcarbamoyl structure (IC50 = 1.0-1.6 mumol/l).

摘要

合成了一系列11种PAF类似物,它们在1位(烷基氨基甲酰氧基)、2位(正丙基)和3位(极性头部基团)进行了结构修饰,并评估了其对人血小板的体外抑制效力。构效关系研究表明,PAF拮抗剂活性受烷基氨基甲酰残基的链长和极性头部基团结构的强烈影响。具有十五烷基和十八烷基氨基甲酰结构的衍生物是有效的抑制剂。二甲基氨基吡啶鎓、P-N距离为3或4个亚甲基且具有十五烷基或十八烷基氨基甲酰结构的类似物表现出最佳活性(IC50 = 1.0 - 1.6 μmol/l)。

相似文献

1
[PAF-antagonists with phospholipid structure. 4. Alkylcarbamoylphospholipids with heteroarene and heterocyclase head groups and variation of the P-N-distance; synthesis, characterization and structure-activity relationship].[具有磷脂结构的血小板活化因子拮抗剂。4. 带有杂芳烃和杂环酶头部基团的烷基氨基甲酰磷脂以及P-N距离的变化;合成、表征及构效关系]
Pharmazie. 1992 Mar;47(3):172-4.
2
[PAF-antagonists with phospholipid structure. 3. Phospholipids with heterocyclane head groups and variations of the phosphorus-nitrogen distance; synthesis, characterization and structure-activity relationship].
Pharmazie. 1991 Nov;46(11):772-4.
3
[PAF-antagonists with phospholipid structure. 2. Phospholipids with heteroarene head groups and variations of the phosphorus-nitrogen distance; synthesis, characterization and structure-activity relationships].[具有磷脂结构的血小板活化因子拮抗剂。2. 带有杂芳烃头基的磷脂及磷氮距离的变化;合成、表征及构效关系]
Pharmazie. 1991 Oct;46(10):708-11.
4
[PAF-antagonists with a phospholipid structure. 5. Propanediol phospholipids with various substituted pyridinium and quinuclidinium head groups and variations of the phosphorus-nitrogen distance;synthesis, characterization and structure activity relationship].[具有磷脂结构的血小板活化因子拮抗剂。5. 带有各种取代吡啶鎓和奎宁环鎓头基以及磷氮距离变化的丙二醇磷脂;合成、表征及构效关系]
Pharmazie. 1993 Jan;48(1):23-6.
5
[PAF-antagonists with lipid structure. 6. Alkylpropandiol lipids with acyl- and ether- structures at the C-3 position and heterocyclic head groups; synthesis, characterization and structure-activity relationship].[具有脂质结构的血小板活化因子拮抗剂。6. C-3位带有酰基和醚结构以及杂环头部基团的烷基丙二醇脂质;合成、表征及构效关系]
Pharmazie. 1997 Sep;52(9):672-5.
6
[PAF-antagonists with a phospholipid structure. 1. Phospholipids with hetero-arene head groups: synthesis, characterization and determination of the action of structural elements].[具有磷脂结构的血小板活化因子拮抗剂。1. 带有杂芳烃头基的磷脂:合成、表征及结构单元作用的测定]
Pharmazie. 1991 Aug;46(8):575-9.
7
Structure-activity relationships in platelet-activating factor (PAF antagonists). 6. Synthesis and in vitro antagonistic activities of 2-substituted 5-oxotetrahydrofurans.
J Lipid Mediat. 1992 Feb;5(1):23-40.
8
Design, synthesis, and structure-activity relationship studies of novel 1-[(1-acyl-4-piperidyl)methyl]-1H-2- methylimidazo[4,5-c]pyridine derivatives as potent, orally active platelet-activating factor antagonists.新型1-[(1-酰基-4-哌啶基)甲基]-1H-2-甲基咪唑并[4,5-c]吡啶衍生物作为强效口服活性血小板活化因子拮抗剂的设计、合成及构效关系研究
J Med Chem. 1996 Jan 19;39(2):487-93. doi: 10.1021/jm950555i.
9
Biochemical characterization of the interaction of lipid phosphoric acids with human platelets: comparison with platelet activating factor.脂质磷酸与人类血小板相互作用的生化特性:与血小板激活因子的比较。
Arch Biochem Biophys. 1994 Jun;311(2):358-68. doi: 10.1006/abbi.1994.1249.
10
Effect of specific antagonists on PAF-induced platelet aggregation and release of plasminogen activator.特异性拮抗剂对血小板活化因子诱导的血小板聚集及纤溶酶原激活物释放的影响。
Biomed Biochim Acta. 1988;47(10-11):S157-60.